CAS: 175414-77-4; Voreloxin

上下游产品

ethyl 1,4-dihydro-7-[(S,S)-3-methoxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylate (3S,4S)-3-methoxy-4-(N-methylammmonio)pyrrolidinium ethyl 7-chloro-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylate ethyl 2-(2,6-dichloro-3-nicotinoyl)-3-(2-thiazolylamino)acrylate

📜3-(2,6-二氯吡啶-3-基)-3-氧代丙酸乙酯置于水,乙酸酐,N,N-二异丙基乙胺,Sodium Hydroxide体系中,用 四氢呋喃,乙醇,水,乙腈 用作溶剂,化学反应 10.0H,反应生成白血病孤儿药
参考文献: Stable Sns-595 Compositions And Methods Of Preparation[fr] Compositions Stables De Sns-595 Et Procédés De Préparation
标题: Stable Sns-595 Compositions And Methods Of Preparation[fr] Compositions Stables De Sns-595 Et Procédés De Préparation
摘要:公开了制备基本纯净的sns-595物质的方法.还提供了含有基本纯净且基本无可见颗粒的sns-595物质的组合物.

专利信息

专利号:US-9295731-B2
优先权日:2013-04-01
标题 :Cleavable drug conjugates, compositions thereof and methods of use
发明人：NGUYEN MARK QUANG
权利人:NGUYEN MARK QUANG
摘要:Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.

专利号:RU-2151770-C1
优先权日:1994-06-14
标 题 :Derivatives of pyridone carboxylic acid, methods of their synthesis, antitumor agent and pharmaceutical composition